EMD
EMYRIA LIMITED
$0.0360
▼ -2.70%
Market cap
$29M
Turnover
$139,253
Last price
$0.0360
Day change
-2.70%
Announcements
18
Range, past year
Open 0.066 · Low 0.023 · Now 0.036 · High 0.078
Open EMD in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
EMD momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
18/100
Wyckoff phase
Accumulation3d
Trend stage
Neutral
1 Day
-2.7%
1 Week
+0.0%
1 Month
-10.0%
1 Year
-44.6%
RSI
38
Avg daily range
6.9%
EMYRIA LIMITED scores 18 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 3 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -30.8%
- High volatility (ATR 6.9%)
- Risk rating: Very High
- Composite downside risk elevated
EMD announcements
Recent price-sensitive releases.
- 2026-10-29 September 2026 Quarterly Activities Report and Appendix 4C Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-09-29 Emyria Successfully Opens First NSW Empax Clinic Progress Report
- 2026-09-10 FDA Selects EMD to Present at Psychedelic Medicines Hearing Progress Report
- 2026-09-08 Emyria Set to Launch First NSW Clinic Progress Report
- 2026-09-08 Emyria Year End Presentation for Investor Webinar Company Presentation
- 2026-08-31 Appendix 4E & Annual Financial Report Year End 30 June 2026 Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-20 Emyria Unlocks Treatment Capacity Progress Report
More Health Care stocks
Most traded in the same sector.